他米巴罗汀靶向RARA过表达:一种强效选择性RARα激动剂治疗急性髓系白血病的新策略
在约30%的非急性早幼粒细胞白血病急性髓系白血病和约50%的骨髓增生异常综合征中存在RARA基因超增强子相关mRNA过表达。2期研究评估口服他米巴罗汀联合阿扎胞苷治疗51例初诊不适合强化疗的AML患者,RARA阳性可评估者完全缓解/完全缓解伴血液学不完全恢复率为61%,耐受性良好。
要点
- RARA过表达见于约30%非APL的AML和约50%的MDS,是可靶向的治疗靶点。
- 他米巴罗汀联合阿扎胞苷在RARA阳性可评估患者中CR/CRi率为61%,CR率50%。
- 联合方案耐受性良好,非血液学不良事件多为低级别,无额外骨髓抑制。
核心结论
- 结果支持进一步评估以他米巴罗汀为基础的治疗策略用于RARA过表达的AML或MDS患者,以提供靶向治疗并改善患者结局。
研究设计与样本
- 2期临床研究评估口服他米巴罗汀联合阿扎胞苷治疗51例初诊不适合强化疗的AML患者,通过基于血液的生物标志物检测外周血原始细胞RARA mRNA过表达,分为RARA阳性(n=22)和RARA阴性(n=29)。
- 试验注册号为NCT02807558。
主要发现
- 在18例可评估疗效的RARA阳性患者中,完全缓解(CR)/完全缓解伴血液学不完全恢复(CRi)率为61%,CR率为50%,至首次复合CR的时间快速,为1.2个月。
- 72%的RARA阳性患者达到输血非依赖。
- 28例可评估疗效的RARA阴性患者缓解率与阿扎胞苷单药治疗一致。
- 他米巴罗汀联合阿扎胞苷耐受性良好,大多数非血液学不良事件为低级别,血液学不良事件与阿扎胞苷单药相当,表明联合治疗未增加骨髓抑制。
- 在RARA高表达的临床前AML模型中证实对他米巴罗汀敏感,而RARA低表达模型不敏感。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A superenhancer at the retinoic acid receptor alpha (RARA) gene is associated with RARA mRNA overexpression in ∼30% of non-acute promyelocytic leukemia acute myeloid leukemia (AML) and in ∼50% of myelodysplastic syndromes (MDS). RARA overexpression is an actionable target for treatment with tamibarotene, an oral potent and selective RARα agonist. Sensitivity to the RARα agonist tamibarotene was demonstrated in RARA-high but not RARA-low preclinical AML models. The combination of oral tamibarotene plus azacitidine was evaluated in a phase 2 clinical study in 51 newly diagnosed unfit patients with AML identified as RARA-positive (n = 22) or RARA-negative (n = 29) for RARA mRNA overexpression in peripheral blasts using a blood-based biomarker test. In 18 response-evaluable RARA-positive patients, complete remission (CR)/CR with incomplete hematologic recovery rate was 61%, CR rate was 50%, and time to initial composite CR was rapid at 1.2 months. Transfusion independence was attained by 72% of RARA-positive patients. In contrast, 28 response-evaluable RARA-negative patients had response rates that were consistent with azacitidine monotherapy. Tamibarotene in combination with azacitidine was well tolerated. The majority of nonhematologic adverse events were low grade and hematologic adverse events were comparable to single-agent azacitidine, demonstrating that there was no additional myelosuppression when tamibarotene was combined with azacitidine. These results support further evaluation of tamibarotene-based treatment strategies in patients with AML or MDS with RARA overexpression to provide a targeted approach with the goal of improving patient outcomes. This trial was registered at www.clinicaltrials.gov as #NCT02807558.
引用
- de Botton S, Cluzeau T, Vigil C, et al. Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood Adv. 2023. PMID: 36477975. doi:10.1182/bloodadvances.2022008806
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。